Gapping down
In reaction to disappointing earnings/guidance:
In reaction to disappointing earnings/guidance:
- SQNS -10.1%, (lowers Q3 guidance), IDT -4.9%, (says continues to work toward the spin-off our non-core assets), PEP -1.3%
M&A news:
- ODP -6.3% (to acquire CompuCom Systems for approx $1 bln; reports prelim Q3 results and lowers full-year outlook)
Other news:
- MNTA -28.6% (after Mylan (MYL) receives FDA approval for a substitutable generic version of Teva's Copaxone 40 mg/mL; Momenta currently has an application for a generic version of Teva's (TEVA) three-times-a-week COPAXONE 40 mg under review by the FDA)
- TEVA -13.7% (MYL receives FDA approval for TEVA's generic Copaxone)
- SBBP -12% (commences public offering of ordinary shares)
- RIGL -7.4% (proposes public offering of $40 mln of common stock)
- NLNK -3.3% (prices offering of 5 mln shares of common stock at $10.25 per share)
- ROKU -2.4% (continued weakness; also CBOE Holdings plans to list options on Roku on Friday October 6)
- AMZN -0.5% (EU Commission finds Luxembourg gave illegal tax benefits to Amazon worth around EUR 250 million), .
Analyst comments:
- ICPT -2.7% (downgraded to Mkt Perform from Mkt Outperform at JMP Securities)
- PRAA -2.5% (downgraded to Sell at Janney)
- WGO -1.4% (downgraded to Hold from Buy at Stifel)
- AAP -0.9% (downgraded to Mkt Perform from Strong Buy at Raymond James
- AN -0.8% (downgraded to Neutral from Buy at Northcoast)
- KHC -0.5% (downgraded to Neutral from Buy at Goldman)
- RSG -0.5% (downgraded to Hold at Stifel)